BioSpace News Archive

Delix Therapeutics announced it has been awarded a $825,000 grant from the U.S. Department of Defense (DOD), to support the advancement of a neuroplastogen for hearing loss treatment.

Bristol Myers Squibb announced the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo® plus Yervoy® compared to investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Obsidian Therapeutics, Inc. today announced the appointment of William Pao, M.D., Ph.D., to the company’s Board of Directors as an independent member.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, announced that it has completed and will commission a new cleanroom facility on its campus in Beloit, Wis. to support clinical trials.

Mission Bio today announced the launch of the Tapestri® Single-cell Multiple Myeloma Multiomics Solution.

Equillium Inc. today announced positive topline data from its Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA), an autoimmune disease driven by an immune cell attack of the hair follicles that causes hair loss.

Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis.

Artelo Biosciences, Inc. today announced that Professor Saoirse O’Sullivan will be presenting new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society.

XORTX Therapeutics Inc. is pleased to announce its participation in the BIO International Convention 2024, being held June 3rd through 6th , 2024.